Finance

Beta
Lists
600276:SHA
Jiangsu Hengrui Pharmaceuticals Co Ltd
CNÂ¥47.08
+0.97%
(+0.45) 1D
Jun 5, 3:00:01 PM GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 600276...
Open
CNÂ¥47.48
High
CNÂ¥48.72
Low
CNÂ¥47.00
Mkt. cap
297.45B
Avg. vol.
85.07M
Volume
93.03M
Dividend
0.42%
Quarterly dividend
CNÂ¥0.05
Ex-dividend date
May 27, 2026
P/E ratio
38.22
52-wk high
CNÂ¥74.04
52-wk low
CNÂ¥46.51
EPS
CNÂ¥1.23
Shares outstanding
3.68B
No. of employees
21K
Open
CNÂ¥47.48
High
CNÂ¥48.72
Low
CNÂ¥47.00
Mkt. cap
297.45B
Avg. vol.
85.07M
Volume
93.03M
Dividend
0.42%
Quarterly dividend
CNÂ¥0.05
Ex-dividend date
May 27, 2026
P/E ratio
38.22
52-wk high
CNÂ¥74.04
52-wk low
CNÂ¥46.51
EPS
CNÂ¥1.23
Shares outstanding
3.68B
No. of employees
21K
News stories
From sources across the web
Profile
Jiangsu Hengrui Pharmaceuticals Company Ltd., also known as Jiangsu Hengrui, is a Chinese pharmaceutical company that manufactures and distributes various types of drug packaging materials, cancer-treating antineoplastics, cardiovascular medication, painkillers, antibiotics, and related products. It is the largest listed pharmaceutical company in China. Wikipedia
About Jiangsu Hengrui Pharmaceuticals Co Ltd
CEO-
Employees20.6K
FoundedApr 28, 1997
Headquarters-
SectorPharmaceutical industry
Websitehengrui.com
Previous reportsAll values in CNY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CNY
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
8.56B
7.43B
8.44B
8.14B
Cost of goods sold
1.06B
1.07B
1.25B
1.09B
Cost of revenue
1.06B
1.07B
1.25B
1.09B
Research and development expenses
1.69B
1.72B
2.02B
1.65B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.12B
3.23B
3.01B
2.81B
Operating expense
4.88B
4.76B
5.35B
4.48B
Total operating expenses
5.93B
5.83B
6.60B
5.57B
Operating income
2.62B
1.60B
1.84B
2.57B
Other non operating income
-11.50M
-154.21M
145.74M
-345.12M
EBT including unusual items
2.98B
1.36B
2.30B
2.56B
EBT excluding unusual items
2.79B
1.68B
1.91B
2.55B
Income tax expense
397.10M
55.51M
338.85M
275.87M
Effective tax rate
13.35%
4.08%
14.76%
10.79%
Other operating expenses
59.00M
-217.30M
326.84M
4.76M
Net income
2.58B
1.30B
1.96B
2.28B
Net profit margin
30.11%
17.52%
23.22%
28.04%
Earnings per share
-
0.20
-
-
Interest and investment income
177.52M
242.14M
288.66M
322.96M
Interest expense
-738.84K
-689.68K
-2.00M
-448.28K
Net interest expenses
176.78M
241.45M
286.66M
322.52M
Depreciation and amortization charges
-
-
-
-
EBITDA
2.82B
1.78B
2.04B
2.77B
Gain or loss from assets sale
-2.31M
2.31M
-4.05M
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer